00000_drug_testing_2019

AbbVie won’t defend its patent for Kaletra so it can be made available for coronavirus treatment

pharmafile | March 26, 2020 | News story | Business Services COVID-19, Ebola Drug, Wuhan Coronavirus, china coronavirus, coronavirus 

AbbVie has announce it will not defend its patent to its HIV therapy Kaletra (lopinavir) so it can be made widely available for potential treatment in coronavirus.

It is the first company to surrender their intellectual property for a potential COVID-19 treatment. This will also allow generic drugmakers to step up their own production of the formula.

The Financial Times reported that this step has been taken after Israel moved to issue a compulsory license for Kaletra to treat the pandemic.

AbbVie also donated supplies of the drug to China this year during the height of its own outbreak. However, clinical trials in the country have been lackluster so far.  The results showed that there was a non-significant trend towards survival as well as the length of hospital stays in patients with severe cases of coronavirus. The trials saw 200 patients tested with the drug. It is thought it may work better in mild cases as part of a combination therapy.

The drug is among many being tested as a coronavirys treatment by the World Health Organization who are also testing the antimalarial drug chloroquine and Ebola drug remdesivir.

Conor Kavanagh

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

diana-polekhina-zbsthwt9vlc-unsplash_2

Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …

Latest content